loading...| Preferred Name |
Mercaptopurine |
|
| Synonyms |
|
|
| Definitions |
A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04) |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C195 |
|
| Accepted_Therapeutic_Use_For |
Acute lymphocytic leukemia; Acute myelogenous leukemia; Crohns disease; Hodgkins lymphoma in children; Lymphoblastic lymphoma; Ulcerative colitis |
|
| ALT_DEFINITION |
A drug used to treat acute lymphatic leukemia. It belongs to the family of drugs called antimetabolites. |
|
| CAS_Registry |
6112-76-1 |
|
| CHEBI_ID |
CHEBI:31822 |
|
| Chemical_Formula |
C5H4N4S.H2O |
|
| code |
C195 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities. Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis. This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04) |
|
| Display_Name |
Mercaptopurine |
|
| FDA_UNII_Code |
E7WED276I5 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Mercaptopurine |
|
| Legacy Concept Name |
Mercaptopurine |
|
| Maps_To |
Mercaptopurine |
|
| NCI_Drug_Dictionary_ID |
43436 |
|
| NSC Number |
755 |
|
| PDQ_Closed_Trial_Search_ID |
43436 |
|
| PDQ_Open_Trial_Search_ID |
43436 |
|
| Preferred_Name |
Mercaptopurine |
|
| prefixIRI |
NCIT:C195 |
|
| prefLabel |
Mercaptopurine |
|
| Semantic_Type |
Pharmacologic Substance Nucleic Acid, Nucleoside, or Nucleotide |
|
| UMLS_CUI |
C0000618 |
|
| subClassOf |